All patients
Age < 65y (younger) Age > 75y (older) ECOG 0 ECOG 1 Gender, female Gender, male P16 negative (HPV) P16 positive (HPV) PDL1 (CPS < 1) PDL1 (CPS >1) PDL1 (TPS <50%) PDL1 (TPS >50%) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mHNSCC - 2nd line (L2), pembrolizumab based treatment vs. chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-040 (all population), 2018 0.80 [0.65; 0.98]
KEYNOTE-040 (CPS >1), 2018 0.74 [0.58; 0.94]
0.77 [0.66 ; 0.90 ] KEYNOTE-040 (all population), 2018, KEYNOTE-040 (CPS >1), 2018 2 0% 882 moderate not evaluable progression or deaths (PFS)detailed results KEYNOTE-040 (all population), 2018 0.96 [0.79; 1.16]
KEYNOTE-040 (CPS >1), 2018 1.01 [0.81; 1.26]
0.98 [0.85 ; 1.13 ] KEYNOTE-040 (all population), 2018, KEYNOTE-040 (CPS >1), 2018 2 0% 882 moderate not evaluable objective responses (ORR)detailed results KEYNOTE-040 (all population), 2018 1.52 [0.88; 2.62]
KEYNOTE-040 (CPS >1), 2018 1.90 [1.04; 3.47]
1.68 [1.12 ; 2.52 ] KEYNOTE-040 (all population), 2018, KEYNOTE-040 (CPS >1), 2018 2 0% 882 moderate not evaluable TRAE (any grade)detailed results KEYNOTE-040 (all population), 2018 0.33 [0.21; 0.51]
0.33 [0.21 ; 0.51 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.24 [0.15; 0.39]
0.24 [0.15 ; 0.39 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-040 (all population), 2018 1.92 [0.35; 10.57]
1.92 [0.35 ; 10.57 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable TRAE leading to discontinuation (any grade)detailed results KEYNOTE-040 (all population), 2018 1.20 [0.55; 2.62]
1.20 [0.55 ; 2.62 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 1.28 [0.53; 3.10]
1.28 [0.53 ; 3.10 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09]
1.91 [0.06 ; 57.09 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.10 [0.01; 0.81]
0.10 [0.01 ; 0.81 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Arthralgia TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.23 [0.03; 2.12]
0.23 [0.03 ; 2.12 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Blood and lymphatic system disorders TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.04 [0.01; 0.31]
0.04 [0.01 ; 0.31 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Cardiac disorders TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Chills TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.47 [0.02; 14.21]
0.47 [0.02 ; 14.21 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Cough TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09]
1.91 [0.06 ; 57.09 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 3.85 [0.43; 34.71]
3.85 [0.43 ; 34.71 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Dyspepsia TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 3.83 [0.17; 85.33]
3.83 [0.17 ; 85.33 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results KEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09]
1.91 [0.06 ; 57.09 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Epistaxis TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Eye disorders TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 1.92 [0.35; 10.57]
1.92 [0.35 ; 10.57 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.05 [0.00; 0.79]
0.05 [0.00 ; 0.79 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Gastritis TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results KEYNOTE-040 (all population), 2018 0.35 [0.14; 0.86]
0.35 [0.14 ; 0.86 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable General disorders and administration site conditions TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.57 [0.23; 1.40]
0.57 [0.23 ; 1.40 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09]
1.91 [0.06 ; 57.09 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Headache TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.47 [0.02; 14.21]
0.47 [0.02 ; 14.21 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 2.01 [0.07; 60.26]
2.01 [0.07 ; 60.26 ] KEYNOTE-040 (all population), 2018 1 0% 495 NA not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results KEYNOTE-040 (all population), 2018 0.95 [0.06; 15.29]
0.95 [0.06 ; 15.29 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Hypersensitivity TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Hypertension TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09]
1.91 [0.06 ; 57.09 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Increase AST TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.31 [0.03; 3.04]
0.31 [0.03 ; 3.04 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.16 [0.01; 3.15]
0.16 [0.01 ; 3.15 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.07 [0.00; 1.17]
0.07 [0.00 ; 1.17 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.47 [0.02; 14.21]
0.47 [0.02 ; 14.21 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Metabolism and nutrition disorders TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.40 [0.10; 1.57]
0.40 [0.10 ; 1.57 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.19 [0.02; 1.61]
0.19 [0.02 ; 1.61 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Musculoskeletal and connective tissue disorders TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09]
1.91 [0.06 ; 57.09 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Myalgia TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.47 [0.02; 14.21]
0.47 [0.02 ; 14.21 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Nervous system disorders TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.47 [0.04; 5.26]
0.47 [0.04 ; 5.26 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.04 [0.01; 0.33]
0.04 [0.01 ; 0.33 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Pancytopenia TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.16 [0.01; 3.15]
0.16 [0.01 ; 3.15 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Peripheral oedema TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09]
1.91 [0.06 ; 57.09 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.06; 15.29]
0.95 [0.06 ; 15.29 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Pruritic rash TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Pruritus generalised TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Pruritus TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.24 [0.01; 5.27]
0.24 [0.01 ; 5.27 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.06; 15.29]
0.95 [0.06 ; 15.29 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results KEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09]
1.91 [0.06 ; 57.09 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results KEYNOTE-040 (all population), 2018 1.44 [0.40; 5.16]
1.44 [0.40 ; 5.16 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Sepsis TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.24 [0.01; 5.27]
0.24 [0.01 ; 5.27 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.54 [0.15; 1.86]
0.54 [0.15 ; 1.86 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results KEYNOTE-040 (all population), 2018 0.31 [0.08; 1.15]
0.31 [0.08 ; 1.15 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Skin exfoliation TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Stevens-Johnson syndrome TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.08 [0.01; 0.65]
0.08 [0.01 ; 0.65 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.09 [0.01; 1.72]
0.09 [0.01 ; 1.72 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Vascular disorders TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Weight decreased TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Back pain AE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Dizziness AE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 06:57 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 278,101,192,114
- treatments: 847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561